{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:42:12Z","timestamp":1792226532899,"version":"4.4.0"},"reference-count":110,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over the last 34\u2009years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3\u20136, 2026. This article provides summaries of eight treatments in preclinical and early clinical development that were presented at EILAT XVIII. These include AUT00206, a positive allosteric modulator of Kv3.1 and Kv3.2 voltage\u2010gated potassium channels in development for the treatment of rare epilepsy syndromes as well as neurodevelopmental and neuropsychiatric disorders; ION283, an antisense oligonucleotide designed to suppress the expression of glycogen synthase 1, under investigation for the treatment of Lafora disease; MSCA\u20107136, a selective allosteric RAS\/mitogen\u2010activated protein kinase\u2014extracellular signal regulated kinase (MEK) inhibitor being developed for the treatment of focal seizures associated with mesial temporal lobe epilepsy and seizures associated with tuberous sclerosis complex; OV329, a selective inhibitor of \u03b3\u2010aminobutyric acid (GABA) aminotransferase, in development for the treatment of drug\u2010resistant focal seizures; PTI5803 (probenecid), an uricosuric agent and a blocker of pannexin 1 channels, repurposed as a treatment for seizures associated with focal cortical dysplasia; simufilam, a filamin A modulator under investigation for the treatment of tuberous sclerosis complex\u2010related epilepsy; SN\u20102000, a selective allosteric phosphodiesterase 4B inhibitor, in development for the treatment of focal seizures; and sodium selenate, a promoter of the dephosphorylation of pathological hyperphosphorylated tau in the brain, under investigation as a disease\u2010modifying agent in mesial temporal lobe epilepsy. Treatments in more advanced clinical development are discussed in an accompanying article.<\/jats:p>","DOI":"10.1002\/epi.70354","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T13:11:10Z","timestamp":1784380270000},"page":"5042-5074","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (\n                    <scp>EILAT XVIII<\/scp>\n                    ). I. Treatments in preclinical and early clinical development"],"prefix":"10.1002","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-4171","authenticated-orcid":false,"given":"Meir","family":"Bialer","sequence":"first","affiliation":[{"name":"Institute for Drug Research, School of Pharmacy, Faculty of Medicine and David R. Bloom Center for Pharmacy The Hebrew University of Jerusalem  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-8912","authenticated-orcid":false,"given":"Cecilie","family":"Johannessen Landmark","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Oslo Metropolitan University  Oslo Norway"},{"name":"The National Centre for Epilepsy, Member of the ERN EpiCare  Oslo Norway"},{"name":"Department of Pharmacology Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8000","authenticated-orcid":false,"given":"Matthias J.","family":"Koepp","sequence":"additional","affiliation":[{"name":"Research Department of Epilepsy UCL Queen Square Institute of Neurology  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[{"name":"Epilepsy Research Centre, Department of Medicine (Austin Health) The University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Neuroscience, School of Translational Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7855-7066","authenticated-orcid":false,"given":"Piero","family":"Perucca","sequence":"additional","affiliation":[{"name":"Epilepsy Research Centre, Department of Medicine (Austin Health) The University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Neuroscience, School of Translational Medicine Monash University  Melbourne Victoria Australia"},{"name":"Bladin\u2010Berkovic Comprehensive Epilepsy Program, Department of Neurology Austin Health  Melbourne Victoria Australia"},{"name":"Department of Neurology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Neurology Alfred Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0554-5352","authenticated-orcid":false,"given":"Torbj\u00f6rn","family":"Tomson","sequence":"additional","affiliation":[{"name":"Department of Clinical Neuroscience Karolinska Institute  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4550-4408","authenticated-orcid":false,"given":"H. Steve","family":"White","sequence":"additional","affiliation":[{"name":"Center for Epilepsy Drug Discovery, Department of Pharmacy, School of Pharmacy University of Washington  Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-8282","authenticated-orcid":false,"given":"Elaine","family":"Wirrell","sequence":"additional","affiliation":[{"name":"Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology Mayo Clinic  Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,18]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18056"},{"key":"e_1_2_16_3_1","article-title":"Progress report on new epilepsy treatments: a summary of the eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development","author":"Bialer M","year":"2026","journal-title":"Epilepsia"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00002.2017"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31537-4"},{"key":"e_1_2_16_6_1","unstructured":"ChoeY HameedM VermudezSA.Rotenberg a positive allosteric modulation of Kv3.1 potassium channels protects against early mortality and seizures in a mouse Dravet syndrome model (abstract). Annual Meeting of the American Epilepsy Society; December 6\u201310 2024 Los Angeles CA. Available from:https:\/\/aesnet.org\/abstractslisting\/positive\u2010allosteric\u2010modulation\u2010of\u2010kv3\u20101\u2010potassium\u2010channels\u2010protects\u2010against\u2010early\u2010mortality\u2010and\u2010seizures\u2010in\u2010a\u2010mouse\u2010dravet\u2010syndrome\u2010model"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2021.08.018"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102610"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52297-3"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101389"},{"key":"e_1_2_16_11_1","unstructured":"HameedM ChoeY HubbsJ BeanB RotenbergA.Developing novel positive allosteric modulators of Kv3.1 potassium channels for seizure control in epilepsy (abstract). Annual Meeting of the American Epilepsy Society; December 5\u20139 2025 Atlanta GA. Available from:https:\/\/aesnet.org\/abstractslisting\/developing\u2010novel\u2010positive\u2010allosteric\u2010modulators\u2010of\u2010kv3\u20101\u2010potassium\u2010channels\u2010for\u2010seizure\u2010control\u2010in\u2010epilepsy"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2018.6107"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17694"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46813-8"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbz019.388"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2012.09.037"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2007.37"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.07.033"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.07.033"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105549"},{"key":"e_1_2_16_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2021.06.006"},{"key":"e_1_2_16_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002037"},{"key":"e_1_2_16_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24104"},{"key":"e_1_2_16_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23899"},{"key":"e_1_2_16_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01434-9"},{"key":"e_1_2_16_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab194"},{"key":"e_1_2_16_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601911"},{"key":"e_1_2_16_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.0473"},{"key":"e_1_2_16_29_1","first-page":"449","article-title":"BRAFV600E expression in neural progenitors results in a hyperexcitable phenotype in neocortical pyramidal neurons","volume":"1232","author":"Goz RU","year":"2020","journal-title":"J Neurophysiol"},{"key":"e_1_2_16_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-022-05571-y"},{"key":"e_1_2_16_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2023.08.019"},{"key":"e_1_2_16_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/epd2.20180"},{"key":"e_1_2_16_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12242"},{"key":"e_1_2_16_34_1","unstructured":"SorensenFNF PetanjekTL ScheperM RydbirkR KorshunovaI AninkJ et\u00a0al.Single\u2010cell profiling of cortical tubers in tuberous sclerosis complex shows molecular structure preservation and massive reorganization of metabolism. bioRxiv.2024;10.31.621014."},{"key":"e_1_2_16_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106890"},{"key":"e_1_2_16_36_1","article-title":"Dynamic control of Raf\u2010ERK signaling modulates neuronal activity across biological scales","volume":"8","author":"Fan H","year":"2026","journal-title":"bioRxiv"},{"key":"e_1_2_16_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1346"},{"key":"e_1_2_16_38_1","doi-asserted-by":"crossref","unstructured":"MotleyWM QuraishiI NolanN FriedmanD LandazuriP RaoV et\u00a0al.Efficacy and tolerability of RAP\u2010219 a potential first\u2010in\u2010class negative allosteric modulator of \u03b38 transmembrane AMPA receptor regulatory protein (TARP\u03b38): impact on RNS long episodes and focal seizures (abstract). Annual Meeting of the American Epilepsy Society December 5\u20139 2025; Atlanta GA. Available from:https:\/\/aesnet.org\/abstractslisting\/efficacy\u2010and\u2010tolerability\u2010of\u2010rap\u2010219\u2010a\u2010potential\u2010first\u2010in\u2010class\u2010negative\u2010allosteric\u2010modulator\u2010of\u2010%CE%B38\u2010transmembrane\u2010ampa\u2010receptor\u2010associated\u2010protein\u2010impact\u2010on\u2010rns\u2010long\u2010episodes\u2010and\u2010focal\u2010seizures","DOI":"10.1212\/WNL.0000000000216447"},{"key":"e_1_2_16_39_1","unstructured":"SarmierePD RoucardC EvrardA FishbackJ.OV329 a GABA aminotransferase (GABA\u2010AT) inhibitor suppresses hippocampal paroxysmal discharges in a human translational mesial\u2010temporal lobe epilepsy (MTLE) mouse model (abstract). Annual Meeting of the American Epilepsy Society December 3\u20137 2021 Chicago IL. Available from:https:\/\/cms.aesnet.org\/abstractslisting\/ov329\u2010\u2010a\u2010gaba\u2010aminotransferase\u2010(gaba\u2010at)\u2010inhibitor\u2010\u2010suppresses\u2010hippocampal\u2010paroxysmal\u2010discharges\u2010in\u2010a\u2010human\u2010translational\u2010mesial\u2010temporal\u2010lobe\u2010epilepsy\u2010(mtle)\u2010mouse\u2010model"},{"key":"e_1_2_16_40_1","unstructured":"SarmierePD ColburnR MukherjeeJ.Evaluation of OV329 a next\u2010generation GABA\u2010AT inhibitor in a series of pharmaco\u2010resistant seizure models through the NINDS Epilepsy Therapy Screening Program (abstract). Annual Meeting of the American Epilepsy Society November 22 2022 Nashville TN. Available from:https:\/\/aesnet.org\/abstractslisting\/evaluation\u2010of\u2010ov329\u2010\u2010a\u2010next\u2010generation\u2010gaba\u2010at\u2010inhibitor\u2010in\u2010a\u2010series\u2010of\u2010pharmaco\u2010resistant\u2010seizure\u2010models\u2010through\u2010the\u2010ninds\u2010epilepsy\u2010therapy\u2010screening\u2010program"},{"key":"e_1_2_16_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17090"},{"key":"e_1_2_16_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17373"},{"key":"e_1_2_16_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106536"},{"key":"e_1_2_16_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/019262338701500203"},{"key":"e_1_2_16_45_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.922"},{"key":"e_1_2_16_46_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.2082"},{"key":"e_1_2_16_47_1","unstructured":"LinS\u2010H VecchioneA ColburnR MukherjeeJ SarmierePD.Low repeat dosing of OV329 enhances GABA\u2010AT inhibition in rodent brain\u2014relationship between pharmacokinetic and pharmacodynamic effects (abstract). Annual meeting of the American Epilepsy Society. December 1\u20135 2023; Orlando FL. Available from:https:\/\/aesnet.org\/abstractslisting\/low\u2010repeat\u2010dosing\u2010of\u2010ov329\u2010enhances\u2010gaba\u2010at\u2010inhibition\u2010in\u2010rodent\u2010brain\u2010\u2010\u2010relationship\u2010between\u2010pharmacokinetic\u2010pk\u2010and\u2010pharmacodynamic\u2010pd\u2010effects"},{"key":"e_1_2_16_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2233464100"},{"key":"e_1_2_16_49_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14317"},{"key":"e_1_2_16_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-021-09818-2"},{"key":"e_1_2_16_51_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00227.2008"},{"key":"e_1_2_16_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207510"},{"key":"e_1_2_16_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar3796"},{"key":"e_1_2_16_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105826"},{"key":"e_1_2_16_55_1","article-title":"Probenecid, an old drug with potential new uses for central nervous system disorders and neuroinflammation","volume":"11","author":"Garc\u00eda\u2010Rodr\u00edguez C","year":"2023","journal-title":"Biomedicine"},{"key":"e_1_2_16_56_1","unstructured":"Actavis Pharma Inc.Probenecid. U.S. prescribing information (last updated April 30 2024). Available from:https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=ae126418\u20105474\u20104fbe\u2010b83c\u2010bde8b2b4ae6e&type=display"},{"key":"e_1_2_16_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1955.00250070099012"},{"key":"e_1_2_16_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-11-39"},{"key":"e_1_2_16_59_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106020-00004"},{"key":"e_1_2_16_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00421568"},{"key":"e_1_2_16_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600711114"},{"key":"e_1_2_16_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180280"},{"key":"e_1_2_16_63_1","unstructured":"DrugBank.Probenecid. (last updated March 14 2026). Available from:https:\/\/go.drugbank.com\/drugs\/DB01032"},{"key":"e_1_2_16_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)23469-3"},{"key":"e_1_2_16_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2012.183"},{"key":"e_1_2_16_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-005-0940-7"},{"key":"e_1_2_16_67_1","doi-asserted-by":"publisher","DOI":"10.31083\/JIN26489"},{"key":"e_1_2_16_68_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay0289"},{"key":"e_1_2_16_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-023-04161-4"},{"key":"e_1_2_16_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi.70227"},{"key":"e_1_2_16_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100469"},{"key":"e_1_2_16_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra055323"},{"key":"e_1_2_16_73_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42494-024-00195-y"},{"key":"e_1_2_16_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.09.009"},{"key":"e_1_2_16_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx364"},{"key":"e_1_2_16_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00357"},{"key":"e_1_2_16_77_1","unstructured":"HagenTJ KurraschDM.Benzothiazole derivatives for treating diseases. WO Patent Application WO2025194063A1. Published 18 September 2025. Priority date 15 March 2024. Available from:https:\/\/patents.google.com\/patent\/WO2025194063A1\/en"},{"key":"e_1_2_16_78_1","unstructured":"KurraschDM IbhazehieboK.Methods of treating epilepsy via phosphodiesterase 4 (PDE4) inhibition. WO Patent Application WO2020154520A1. Published 30 July 2020. Available from:https:\/\/patents.google.com\/patent\/WO2020154520A1\/en"},{"key":"e_1_2_16_79_1","doi-asserted-by":"publisher","DOI":"10.1101\/2025.05.13.653835"},{"key":"e_1_2_16_80_1","doi-asserted-by":"crossref","unstructured":"KinchCD KeslerM RhaS DograD MorinK RhoJ et\u00a0al.Allosteric inhibition of phosphodiesterase\u20104B (PDE4B) as a broad\u2010spectrum therapeutic strategy for refractory epilepsy (abstract). Annual Meeting of the American Epilepsy Society: December 5\u20139 2025; Atlanta GA. Available from:https:\/\/aesnet.org\/abstractslisting\/allosteric\u2010inhibition\u2010of\u2010phosphodiesterase\u20104b\u2010as\u2010a\u2010broad\u2010spectrum\u2010therapeutic\u2010strategy\u2010for\u2010refractory\u2010epilepsy","DOI":"10.1101\/2025.05.13.653835"},{"key":"e_1_2_16_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1407871"},{"key":"e_1_2_16_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117009"},{"key":"e_1_2_16_83_1","article-title":"Phosphodiesterase 4 inhibition in neuropsychiatric disorders associated with Alzheimer's disease","volume":"14","author":"Chen J","year":"2025","journal-title":"Cells"},{"key":"e_1_2_16_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01321-w"},{"key":"e_1_2_16_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.04.020"},{"key":"e_1_2_16_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.915460"},{"key":"e_1_2_16_87_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww116"},{"key":"e_1_2_16_88_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009038107"},{"key":"e_1_2_16_89_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.78877"},{"key":"e_1_2_16_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr209"},{"key":"e_1_2_16_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01107.x"},{"key":"e_1_2_16_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.12.005"},{"key":"e_1_2_16_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605798"},{"key":"e_1_2_16_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz381"},{"key":"e_1_2_16_95_1","first-page":"1","article-title":"NTP technical report on toxicity studies of sodium selenate and sodium selenite (CAS Nos. 13410\u201001\u20100 and 10102\u201018\u20108) administered in drinking water to F344\/N rats and B6C3F1 mice","volume":"38","author":"Abdo KM","year":"1994","journal-title":"Toxic Rep Ser"},{"key":"e_1_2_16_96_1","first-page":"1","article-title":"Bioassay of selenium sulfide (gavage) for possible carcinogenicity (CAS No. 7446\u201034\u20106)","volume":"194","author":"National Toxicology Program","year":"1980","journal-title":"Natl Toxicol Program Tech Rep Ser"},{"key":"e_1_2_16_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/0890-6238(90)90057-3"},{"key":"e_1_2_16_98_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-075888"},{"key":"e_1_2_16_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70531"},{"key":"e_1_2_16_100_1","unstructured":"Epilepsy Society of Australia.Australian Epilepsy Clinical Trial Network. Available from:https:\/\/epilepsy\u2010society.org.au\/aectn\/"},{"key":"e_1_2_16_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000223"},{"key":"e_1_2_16_102_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0662-z"},{"key":"e_1_2_16_103_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160544"},{"key":"e_1_2_16_104_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12299"},{"key":"e_1_2_16_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-040100"},{"key":"e_1_2_16_106_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055019"},{"key":"e_1_2_16_107_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001456"},{"key":"e_1_2_16_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0395-9"},{"key":"e_1_2_16_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12490"},{"key":"e_1_2_16_110_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001256"},{"key":"e_1_2_16_111_1","article-title":"Potential for therapeutic alteration of the underlying biology of epilepsy","volume":"13","author":"Sperling MR","year":"2025","journal-title":"Biomedicine"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi.70354","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/epi.70354","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/epi.70354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:27:19Z","timestamp":1792225639000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/epi.70354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,18]]},"references-count":110,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/epi.70354"],"URL":"https:\/\/doi.org\/10.1002\/epi.70354","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,18]]},"assertion":[{"value":"2026-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}